Skip to content

SION SION Business Segments — Net loss

Similar metrics at other companies

Immunovant, Inc. logo
IMVTReportable Segment — Net loss
$147.86M+38.9%
Viridian Therapeutics, Inc. logo
VRDNReportable Segment — Net loss
-$104.9M-20.7%
Biohaven logo
BHVNReportable Segment — Net loss
-$130.53M+41.1%
Arcus Biosciences logo
RCUSReportable segment — Net loss
-$128M-14.3%
Crinetics Pharmaceuticals logo
CRNXReportable Segment — Net loss
-$127.85M-32.1%
GRAIL, Inc. logo
GRALReportable Segment — Net loss
-$93.19M+12.3%

Other financials

Income statement

See full
Operating income-$29.6M-50.6%
Net income-$26.8M-62.5%
EPS (diluted)-$0.60+3.2%

Balance sheet

See full
Cash & equivalents$64.3M-23.2%
Total debt$8.4M-11.8%
Total equity$288.2M-18.1%
Total assets$305.0M-17.5%

Cash flow

See full
Operating cash flow-$21.8M-34.1%
CapEx--100%
Free cash flow-$21.8M-33.4%

Valuation

See full
Market cap$1.8B
Enterprise value$1.74B

Returns & leverage

See full
Return on equity-26.7%
Debt / equity0.0×
Current ratio22.6×-6.1×

Where this comes from

Reported directly by SION in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The official record: SION’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about SION's business segments — net loss.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is SION's business segments — net loss?
SION (SION) reported business segments — net loss of -$26.78M in Q1 2026.
How has SION's business segments — net loss changed year-over-year?
SION's business segments — net loss decreased by 62.5% year-over-year, from -$16.48M to -$26.78M.
What does business segments — net loss mean?
Represents the total financial loss generated by a specific business segment after accounting for all allocated revenues and operating expenses. For clinical-stage companies, this metric serves as a primary indicator of the segment's current cash burn rate and financial sustainability. It highlights the extent to which the segment's activities are funded by corporate capital rather than self-generated revenue.